SCHEMBL25317158

SCHEMBL25317158

Cc1cc(C(=O)N2CCN(c3ccc(F)cn3)CC2)cc(C=O)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KDM4E B2RXH2 8/20 0.44
LMNA P02545 4/20 0.43
HTT P42858 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MGLL Q99685 1/20 0.42
HRH3 Q9Y5N1 2/20 0.41
PPARG P37231 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ME2 P23368 2/20 0.41
ME1 P48163 2/20 0.41
ME3 Q16798 2/20 0.41
ERN1 O75460 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29475509 1.00 MEN1 (0.46) MEN1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL20140581 0.81 KDM4E (0.52) MEN1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL20140681 0.80 ALDH1A1 (0.52) MEN1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL25320569 0.78 KCNQ3 (0.44) MEN1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL29475575 0.78 KCNQ3 (0.44) MEN1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL20140026 0.77 KDM4E (0.57) MEN1KMT2ACYP2C9CYP2C19KDM4E
SCHEMBL20141517 0.77 KDM4E (0.49) MEN1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL29475592 0.76 KCNQ3 (0.43) MEN1KMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL25318966 0.76 KCNQ3 (0.43) MEN1KMT2ACYP1A2CYP2C9CYP2C19
Trifluoroacetic Acid SCHEMBL25316419 0.72 KDM4E (0.40) MEN1KMT2ACYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043395-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING NEUROPORE THERAPIES, INC. 2024-02-08 US claimed
EP-4217342-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING Neuropore Therapies, Inc. (US) 2023-08-02 EP claimed
CN-116507607-A Compounds and compositions as modulators of TLR signaling 神经孔疗法股份有限公司 2023-07-28 CN claimed
US-20240043395-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING NEUROPORE THERAPIES, INC. 2024-02-08 US disclosed
EP-4217342-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING Neuropore Therapies, Inc. (US) 2023-08-02 EP disclosed
CN-116507607-A Compounds and compositions as modulators of TLR signaling 神经孔疗法股份有限公司 2023-07-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043395-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING TLR3, TLR6, TLR4 MEN1 4871/4885KMT2A 4366/4885CYP1A2 4857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.